ACEA Pharma

ACEA Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule targeted therapies for cancer and autoimmune diseases. The company's lead asset, abivertinib, is a next-generation tyrosine kinase inhibitor targeting EGFR mutations in non-small cell lung cancer and Bruton's tyrosine kinase for B-cell malignancies. ACEA was acquired by Sorrento Therapeutics in 2021 to bolster its oncology and inflammation pipeline with late-stage assets and established manufacturing capabilities. The company maintains a significant presence in both San Diego, California, and Hangzhou, China, facilitating global clinical development and commercialization efforts. Its portfolio also includes several early-stage inhibitors targeting various kinase-driven pathways.